Clusterin is a heterodimeric glycoprotein with wide range of functions. To further explore its possible regulatory role in energy homeostasis and in adipose tissue, we measured plasma clusterin and its mRNA expression in subcutaneous adipose tissue (SCAT) of 15 healthy lean women, 15 obese women (OB) and 15 obese women with type 2 diabetes mellitus (T2DM) who underwent a 2-week very low-calorie diet (VLCD), 10 obese women without T2DM who underwent laparoscopic sleeve gastrectomy (LSG) and 8 patients with T2DM, 8 patients with impaired glucose tolerance (IGT) and 8 normoglycemic patients who underwent hyperinsulinemic euglycemic clamp (HEC). VLCD decreased plasma clusterin in OB but not in T2DM patients while LSG and HEC had no effect. Clusterin mRNA expression in SCAT at baseline was increased in OB and T2DM patients compared with controls. Clusterin mRNA expression decreased 6 months after LSG and remained decreased 12 months after LSG. mRNA expression of clusterin was elevated at the end of HEC compared with baseline only in normoglycemic but not in IGT or T2DM patients. In summary, our data suggest a possible local regulatory role for clusterin in the adipose tissue rather than its systemic involvement in the regulation of energy homeostasis.
INTRODUCTION
Clusterin, also known as apolipoprotein J (ApoJ), sulfated glycoprotein-2 (SGP-2), SP 40,40 and under numerous other names, is a heterodimeric glycoprotein with a molecular weight of 70-80kDa. It was isolated for the first time in 1983 as a protein capable of aggregation of Sertoli cells to clusters (Blaschuk et al. 1983 , Fritz et al. 1983 . Clusterin is expressed by most of the tissues and is present also in plasma, breast milk, cerebrospinal fluid and semen (Aronow et al. 1993 , Choi-Miura et al. 1992 , Kounnas et al. 1995 . Clusterin has multiple functions including those in lipid transport, complement inhibition, regulation of sperm maturation, inflammation, cell migration and apoptosis (Jenne et al. 1991 , Trougakos et al. 2002 . Its higher levels are associated with Alzheimer dementia, type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases (Song et al. 2012 , Trougakos et al. 2002 . Nevertheless, its main function still remains to be defined. It is possible that clusterin has either multiple different independent functions in the body or it may have some universal regulatory function such as acting as a chaperon protecting cells in different tissues from stress (Humphreys et al. 1999 ).
Approximately 40-60 % of circulating clusterin is bound to apolipoprotein A-I as a part of the high density lipoprotein (HDL) (James et al. 1991 , Jenne et al. 1991 ; however, it can also be part of low or very low density lipoprotein (LDL, VLDL) (Hoofnagle et al. 2010 , Pettersson et al. 2011 . Clusterin also creates binding complexes with leptin which could be part of the HDL or non-lipoprotein part of blood serum (Bajari et al. 2003) . In in vitro studies, clusterin-leptin complex is able to bind to both leptin and LDL receptors (Bajari et al. 2003) .
Therefore, it has been suggested that clusterin could act as a regulator of leptin activity (Bajari et al. 2003) . Nevertheless, other data do not support such conclusion. For example: Arnold and colleagues (Arnold et al. 2011) have shown that in the group of obese adolescents before and after weight reduction only 1 % of serum leptin was bound to clusterin or HDL and that there were no correlations between serum clusterin and leptin. Poulakou and colleagues (Poulakou et al. 2008) even found an inverse relationship between serum clusterin and leptin or HDL, respectively, in patients with coronary heart disease. No clear relationship was identified between BMI and serum clusterin levels (Arnold et al. 2011 , Kujiraoka et al. 2006 , Poulakou et al. 2008 . Nevertheless, weight loss induced both by hypocaloric diet and laparoscopic gastrectomy was found to lower serum clusterin levels in some studies (Arnold et al. 2011 , Oberbach et al. 2011 .
Information on the possible role of clusterin in the regulation of adipose tissue function or in the etiopathogenesis of type 2 diabetes mellitus (T2DM) is conflicting. While in some studies patients with T2DM had higher plasma clusterin concentrations which positively correlated with plasma glucose levels (Kujiraoka et al. 2006 , Trougakos et al. 2002 , in another study no difference in clusterin levels between healthy and diabetic patients was found (Poulakou et al. 2008) . T2DM patients had also a lower percentage of clusterin in HDL We have identified clusterin by low density Protein Array as one of the proteins being markedly increased in the adipose tissue of obese patients suggesting that it may also have a local regulatory role in adipose tissue and its metabolic changes in obesity. To this end, we measured mRNA expression of clusterin in adipose tissue and its plasma concentrations in obese patients with and without type 2 diabetes mellitus and explored its modulation by different intervention to gain further insight into its possible regulatory role in the adipose tissue.
METHODS

Study subjects and interventions
This paper presents the data from three substudies. Fifteen obese women (OB group) and fifteen obese women with type 2 diabetes mellitus (T2DM group) who underwent a 2-week very low-calorie diet (VLCD) with energy intake 2500kJ per day (600 kcal per day) were included into the first substudy. During the reduction program all patients were hospitalized at the Third Department of Medicine, General University Hospital in Prague.
Ten obese women without T2DM who underwent laparoscopic sleeve gastrectomy (LSG; LSG-OB group) at the Surgical Clinic, Central Military Hospital in Prague were included into the second substudy. The patients were referred to LSG based on the criteria recommended by European Obesity Society (Fried et al. 2013) .
As a control group for the substudy one and two, fifteen healthy lean women (BMI 20-25kg/m 2 ) were included.
Eight patients with T2DM (H-T2DM group), eight patients with impaired glucose tolerance (H-IGT group) and eight normoglycemic patients (H-NGT group) who underwent euglycemic hyperinsulinemic clamp (HEC) were included into the third substudy. Each group in this substudy consisted of 4 men and 4 women and all patients had BMI between 20 and 35 kg/m 2 . HEC was initiated by continuous insulin infusion with the rate of 2 mIU/kg/min for patients with BMI < 30kg/m 2 or 80 mIU/m 2 /min for patients with BMI ≥ 30kg/m 2 . After 5min, the infusion rate was reduced by half and maintained at this level till the end of the test.
Plasma glucose levels were measured every 5 minutes throughout the test. To achieve euglycemia, glucose infusion was started 5min after the start of insulin infusion. The glucose infusion rate was adjusted during the test in order to achieve normoglycemia between 150 and (MCR glc /I -ml*kg -1 *min -1 per µIU*ml -1 ) was calculated as the metabolic clearance rate for glucose (MCR glc , ml.kg -1 .min -1 ) divided by the mean insulin concentration during steady state.
The body weight of all study participants remained stable for at least three months before the enrollment into the study. Written informed consent was signed by all participants before beginning of the study. The study was approved by Human Ethical Review Committee, First
Faculty of Medicine and General University Hospital, Prague, Czech Republic and was performed in accordance with the guidelines proposed in the Declaration of Helsinki.
Anthropometric examination, blood and adipose tissue sampling
Control subjects and subjects who underwent HEC were examined only once. Patients included in the reduction program (T2DM and OB group) were examined twice; at baseline and after 2 weeks of VLCD. Obese patients who underwent LSG (LSG-OB group) were examined three times; at baseline (1 week before LSG), 6 and 12 months after surgery.
All subjects were measured and weighted, and their BMI was calculated. Blood samples for biochemical and hormonal measurements were withdrawn after 12 h of overnight fasting.
Blood samples were separated by centrifugation for 10 min at 1000 x g within 30 min from blood collection. Serum and plasma samples were subsequently stored in aliquots at -80 °C until further analysis.
Samples of subcutaneous adipose tissue for mRNA expression analysis were obtained from abdominal region by subcutaneous needle aspiration biopsy. All samples were taken from approximately the same location. In HEC substudy, the samples were obtained 30 min before the start of HEC and 30 min after the end of HEC. Approximately 100 mg of adipose tissue was collected to 1 ml of RNA stabilization Reagent (RNAlater, Qiagen, Hilden, Germany) and stored at -80 °C until further analysis.
Hormonal and biochemical assays
Plasma clusterin levels were measured by a commercial ELISA kit (BioVendor, Brno, Czech Republic). Sensitivity was 0.5 ng/ml, inter-and intraassay variability were <7 % and <9 %, respectively.
Plasma leptin concentrations were measured by a commercial ELISA kit (BioVendor, Brno, Czech Republic) with a sensitivity 0.12 ng/ml. Serum insulin concentrations were measured by commercial RIA kit (Cis Bio International, Gif-sur-Yvette Cedex, France) with a sensitivity 2.0 IU/ml. Serum C-reactive protein (CRP) levels were measured by high sensitive assay (eBioscience, Vienna, Austria) with a sensitivity 3 pg/ml. The intra-and interassay variabilities of all methods were less than 5 % and less than 10 %, respectively.
Biochemical parameters (glucose, glycated hemoglobin, triglycerides, total and HDL cholesterol) were measured and LDL cholesterol was calculated in the Department of Biochemistry of General University Hospital by standard laboratory methods. The homeostasis model assessment index (HOMA-IR) was calculated using the following formula: (fasting serum insulin (mIU/l) × fasting serum glucose (mmol/l))/22.5.
Determination of mRNA expression
Samples of subcutaneous adipose tissue were homogenized on a MagNA Lyser Instrument using MagNA Lyser Green Beads (Roche Diagnostics GmbH, Germany). Total RNA was extracted from the homogenized sample on MagNA Pure instrument using MagNA Pure
Compact RNA Isolation (Tissue) kit (Roche Diagnostics GmbH, Germany). The RNA concentration was determined from absorbance at 260 nm and the integrity of RNA was controlled by 260/280 nm absorbance ratio (NanoPhotometer, Implen, Munchen, Germany).
Reverse transcription was performed using 0.25 μg of total RNA to synthesize the first strand 
Comparison of the amount of selected proteins in subcutaneous adipose tissue between control, obese and T2DM patients using low density Protein Array
Samples of subcutaneous adipose tissue were sonicated 10 minutes on ice-cold homogenization buffer [150 mM NaCl, 2 mM EDTA, 10 % glycerol, 25 mM benzamidine, 1 mM PMSF, and protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA) in 10 mM
Tris-HCl (pH 7.0)]. The homogenate was centrifuged at 3,000 x g for 15 min at 4 °C, the fat cake was then discarded and the homogenate was centrifuged again at 14,000 x g for 20 min at 4 °C. The supernatant was stored in aliquots at -80 °C. Total amount of protein in each sample was assessed using the Bradford method with Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using BSA as a standard.
350 μg of total protein was transferred to each Human Apoptosis Antibody Array (R&D System, Inc., Minneapolis, MN, USA) and array was processed according to the manufacturer instruction.
Detection of membrane antibody binding was evaluated by SuperSignal West Dura
Chemiluminescent ECL Substrate (Pierce Biotechnology, Inc., Rockford, IL, USA). Signals were visualized and evaluated on a G:Box iChemi XT Bio instrument (Syngene, Cambridge, U.K.). Results were analyzed and the quantifications of bands were calculated using GeneTools Software (Syngene, Cambridge, U.K.).
For the pilot scan of 35 proteins in adipose tissue, samples from a control subject (age 51 yrs; BMI 23.3 kg/m 2 ), an obese subject without T2DM (age 60 yrs; BMI 50.0 kg/m 2 ) and an obese woman with T2DM before and after VLCD (age 49 yrs; BMI 74.6 kg/m 2 vs. 69.6 kg/m 2 ) were used.
Statistical analysis
Statistical analysis was performed on SigmaPlot 13.0 software (Systat Software, Inc., San
Jose, CA, USA). Prior to analysis, all continuous variables were assessed for normality.
Anthropometric, hormonal and biochemical results are expressed as means ± SEM (standard error of the means).
Differences between control group and obese and/or T2DM patients were evaluated using Statistical significance for all tests was assigned to p value < 0.05.
RESULTS
Difference in the amount of selected proteins in subcutaneous adipose tissue between control, obese and T2DM patients using low density Protein Array
For the pilot scan of 35 proteins in adipose tissue, samples of 1 patient in each group were used. As such, it was not possible to evaluate these data statistically.
After correction to positive controls, the detected amount of clusterin in the sample of SCAT from the obese patient was 9.92times higher and from the T2DM patient before VLCD 0.54times and after VLCD 1.36times higher compared with the control subject ( Figure 1 ).
The influence of VLCD on hormonal and biochemical parameters and mRNA expression in T2DM and OB patients
Clinical, hormonal and metabolic characteristics and mRNA expression of the control group and OB and T2DM patients before and after 2 weeks of VLCD are shown in Table 1 .
As expected, BMI, body fat, waist circumference, HOMA index, serum insulin, CRP and leptin concentrations were higher in both obese and T2DM group at baseline relative to control subjects. Fasting blood glucose, glycated hemoglobin and triglycerides were higher and HDL cholesterol was lower only in T2DM group relative to control subjects. There were no significant differences between the groups at baseline in the LDL and total cholesterol.
Two weeks of VLCD decreased BMI, waist circumference, HDL and total cholesterol in both obese and T2DM group, decreased body fat, CRP and leptin in obese group only and decreased LDL cholesterol in T2DM group only. Two weeks of VLCD did not influence fasting blood glucose, triglycerides and insulin levels. Relative gene mRNA expression of leptin did not differ between study groups at baseline and was not influenced by VLCD.
Plasma clusterin levels did not differ between OB, T2DM and control groups at baseline.
Two weeks of VLCD decreased clusterin in the obese group whereas its levels in T2DM group were not influenced. Clusterin mRNA expression at baseline was higher in both OB and T2DM groups and remained elevated after VLCD. There were no significant differences in clusterin plasma levels and mRNA expression between OB and T2DM groups.
The effect of LSG on hormonal and biochemical parameters and mRNA expression in obese non-diabetic patients
Clinical, hormonal and metabolic characteristics and mRNA expression of the control group and OB patients before and 6 and 12 months after LSG are shown in Table 2 .
BMI, body fat, waist circumference, HDL cholesterol, fasting insulin, HOMA index, CRP and leptin concentrations were higher in obese group before laparoscopic sleeve gastrectomy (LSG) compared with control subjects. At baseline, there were no significant differences in glycated hemoglobin, triglycerides, LDL and total cholesterol.
Six months after LSG BMI, body fat, waist circumference, CRP and leptin levels were decreased. All these values remained decreased 12 months after LSG compared with baseline.
Triglyceride levels were decreased and HDL cholesterol increased only 12 months after the LSG. Fasting blood glucose, glycated hemoglobin, total cholesterol, fasting insulin and HOMA index were not affected by LSG.
Plasma clusterin levels did not differ between obese and control groups at baseline and were not affected by LSG.
mRNA expression of both leptin and clusterin was higher in obese patients before LSG compared with control group. Clusterin mRNA remained elevated both 6 and 12 months after LSG, whereas leptin mRNA decreased 6 months after LSG to the levels comparable with control group while increasing again 12 months after LSG.
The effect of euglycemic hyperinsulinemic clamp on hormonal and biochemical parameters and mRNA expression in NGT, IGT and T2DM patients
The clinical, hormonal and metabolic characteristics of the patients who underwent hyperinsulinemic euglycemic clamp (HEC) are shown in Table 3 . There was no difference between the genders in basal plasma clusterin in the combined population of all patients (52.3 ± 3.4 ng/ml for males vs. 47.0 ± 3.9 ng/ml for females; p = 0.322). Similarly, there were no significant differences between groups in plasma clusterin during HEC (data not shown).
Compared with normoglycemic patients (NGT), the impaired glucose tolerance (IGT) and T2DM group had higher fasting blood glucose and HOMA index and were slightly older. In addition, T2DM group had higher glycated hemoglobin and HOMA index compared with NGT group and reduced HDL cholesterol compared with both NGT and IGT, whereas total cholesterol was lower compared with IGT group. There were no significant differences between groups in basal leptin.
Analogously, no significant differences between groups in the basal mRNA expression of clusterin and leptin could be observed. At the end of HEC, mRNA expression of clusterin was increased compared with baseline in the NGT group but not in the IGT and T2DM groups.
mRNA expression of leptin was increased at the end of HEC compared with baseline in the IGT group but not in the NGT and T2DM patients (Table 3) .
We did not find any significant relationships between plasma clusterin area under the curve or its mRNA expression and insulin sensitivity index (data not shown).
Relationship of plasma clusterin levels and its mRNA expression in SCAT to other studied parameters
The relationship of plasma clusterin levels and its mRNA expression in SCAT to other studied parameters was calculated in a combined population of healthy controls, OB, IGT and T2DM subjects at baseline and in the combined population consisting only of subjects with normal glucose tolerance (healthy controls and OB subjects at baseline) (Table 4) .
Plasma clusterin correlated positively with BMI, body fat and leptin and inversely with age in the combined group including IGT and T2DM patients but not in the group without IGT and T2DM patients. On the contrary, plasma clusterin correlated positively with fasting insulin only in the combined group without IGT and T2DM patients.
In both combined groups (with or without T2DM patients) mRNA clusterin correlated positively with BMI, body fat, waist circumference, serum triglycerides, fasting insulin, HOMA index, CRP, leptin and leptin mRNA in SCAT.
We could not find a correlation between plasma clusterin and plasma leptin or between plasma clusterin and mRNA clusterin in SCAT.
According to the multiple linear regression model, none of the parameters included was an independent predictor of plasma clusterin levels in a combined group without T2DM and IGT patients. Plasma clusterin levels in the combined group of all patients, including T2DM and IGT, could be predicted only from one independent variable -age with p=0.004 and the adjusted R 2 = 0.099. The clusterin mRNA levels in both combined groups could be predicted from a linear combination of two independent variables: leptin mRNA expression (p<0.001) and waist circumference (p<0.001) -the adjusted R 2 was 0.645 for the group without T2DM
and IGT and 0.598 for the group of all patients.
DISCUSSION
We have identified clusterin by low density Protein Array as one of the proteins being markedly increased in the adipose tissue of obese patients suggesting that it may also have a local regulatory role in adipose tissue and its metabolic changes in obesity. To this end, we measured its mRNA expression and plasma concentrations in obese patients with and without type 2 diabetes mellitus and explored its modulation by different interventions to gain further insight into its possible regulatory role in the adipose tissue.
In our study, we found no significant differences in circulating clusterin levels between 
2014). In this study, we investigated whether very-low-calorie diet (VLCD) and laparoscopic
sleeve gastrectomy (LSG) affect plasma clusterin concentrations or its mRNA expression in subcutaneous adipose tissue in obese patients with or without T2DM. We found a marked decrease in plasma clusterin after 2 weeks of VLCD in obese but interestingly not in T2DM patients. The reason for this differential response is not clear. One of the possible explanations could be the fact that metabolic derangements in patients with obesity and type 2 diabetes are more profound and a shorter intervention with very-low-calorie diet was not sufficient enough to induce complete systemic changes (Galgani et al. 2008) . Alternatively, considering the similar direction of difference and comparable post-interventional plasma clusterin levels in both groups, the absence of a clear effect of VLCD in T2DM subjects could be the result of a relatively small number of patients in the group. Nevertheless, the lack of changes in plasma clusterin concentrations after LSG argues against its direct regulation by weight reducing interventions or against its significant role in the modulation of energy homeostasis.
Along the same lines, we were not able to find any correlation between plasma clusterin and BMI, body fat or waist circumference in the combined group of patients without IGT and T2DM. This is in agreement with some of the previous studies (Arnold et al. 2011 , Kujiraoka et al. 2006 , Poulakou et al. 2008 ) which also did not find any relationship between circulating clusterin and BMI. In our study, we also examined sex-dependent differences in plasma clusterin levels. The study by Poulakou and colleagues (Poulakou et al. 2008) showed higher levels of clusterin in male compared with female subjects. In our study we did not find any gender differences, which could have been due to the relatively low number of subjects included or their different characteristics as compared to Poulakou´s study.
According to the available data, about 40-60 % of clusterin in circulating blood is supposed to be part of the HDL particle, where it is bound to apolipoprotein-A1 (James et al. et al. 2010 et al. , Pettersson et al. 2011 . There is a strong inverse relationship between the amount of clusterin in HDL and in LDL/VLDL (Hoofnagle et al. 2010) . With respect to these data it is interesting to note, that we did not find any correlation between plasma clusterin and HDL or LDL cholesterol. Clusterin probably also creates complexes with leptin and acts as a regulator of leptin activity, although the importance of this mechanism is controversial (Arnold et al. 2011 , Bajari et al. 2003 . In our study, we found only a weak correlation of plasma clusterin with plasma leptin in the combined group of all patients and no correlation in the group without IGT and T2DM subjects. This result is in accordance with the results of Arnold and colleagues (Arnold et al. 2011 ) who also did not find any such relationship.
1991, Jenne et al. 1991). It also could be part of the low density lipoprotein (LDL) (Hoofnagle
To our best knowledge, no information regarding the clusterin mRNA expression in adipose tissue is currently available. In our study, clusterin mRNA expression in SCAT was increased compared with control group in both OB and T2DM groups and remained increased after 2 weeks of VLCD. On the contrary, 6 months after LSG clusterin mRNA expression was decreased by 30 % compared with baseline and remained lower by 23 % even 12 months after LSG. In other tissues, clusterin was identified as the gene whose increased expression could indicate the repair or remodeling of damaged tissue (Hoofnagle et al. 2010 , Jenne et al. 1991 .
One of the consequences of obesity is increased rate of apoptosis and cell death in adipose tissue. In vivo, clusterin expression appears to be associated with cell survival (Humphreys et al. 1999) . It is therefore tempting to speculate that increased mRNA expression of clusterin in adipose tissue in obese patients could be the marker of a compensatory mechanism protecting the tissue against apoptosis as a result of weight-reducing interventions. This possibility is also supported by the fact that in the multiple linear regression model clusterin mRNA expression in SCAT could be predicted from leptin mRNA expression together with waist circumference.
One of the proposed roles of clusterin bound with HDL cholesterol is its beneficial influence on atherosclerosis, since the lack of clusterin in HDL particles impairs the lipoprotein's cardioprotective functions (Hoofnagle et al. 2010 , James et al. 1991 . Increased amount of clusterin was found in arterial wall during the development of atherosclerosis (Trougakos et al. 2002) . Clusterin in the HDL complex probably serves as a regulator of lipid transport and local lipid redistribution but not as the molecule transporting lipids itself (Jenne et al. 1991 , Trougakos et al. 2002 .
One of the primary actions of clusterin could be the repression of inflammation (Kounnas . Thus we could hypothesize that clusterin might have an anti-inflammatory function also in adipose tissue, which role could be another explanation for its elevated mRNA expression in subcutaneous adipose tissue of obese patients that is typically characterized by chronic low-grade inflammation. This idea is also supported by the fact that in our study clusterin mRNA expression in SCAT of both combined groups with or without T2DM patients correlated positively not only with markers of obesity (BMI, body fat, waist circumference) but also with serum triglycerides, fasting insulin, HOMA index and the inflammatory marker CRP. Chronic low-grade inflammation in obese subject is one of the mechanisms contributing to the development of atherosclerosis and thus the antiinflammatory effect of clusterin could also be protection against atherosclerosis. On the contrary, the fact that ApoE-KO mice with decreased expression of nuclear clusterin have reduced atherosclerotic lesions argues against its antiatherosclerotic role (Hamada et al.
2011).
While a strong positive correlation between clusterin levels in HDL particles and insulin sensitivity was found in humans (Hoofnagle et al. 2010) , little is known about the acute regulatory role of insulin and glucose in the changes of clusterin mRNA expression. In the primary hepatocytes and hepatoma cell lines, high glucose concentrations increased clusterin expression (Kim et al. 2011) . To assess the effect of insulin and glucose levels on plasma levels and mRNA expression of clusterin in SCAT, we performed a hyperinsulinemic euglycemic clamp (HEC). We could not find any significant changes in plasma clusterin levels during HEC in any of the studied groups or any relationship between plasma clusterin area under the curve or its mRNA expression and insulin sensitivity index. mRNA expression of clusterin was elevated at the end of HEC compared with baseline only in the normoglycemic group, but not in the IGT or T2DM group. The explanation of this phenomenon remains unclear and warrants further investigations.
In summary, plasma clusterin concentrations did not differ between healthy subjects and obese patients with or without type 2 diabetes mellitus and they were only partially influenced by short-term weight reduction. On the contrary, clusterin mRNA expression in subcutaneous fat was higher in obese and T2DM patients compared with lean controls and it decreased after bariatric surgery but not after short-term caloric restriction. Clusterin mRNA correlated positively with markers of obesity, serum triglycerides, fasting insulin, HOMA index and the inflammatory marker CRP. Taken together, our data suggest a possible local regulatory role for clusterin in the adipose tissue rather than its systemic involvement in the regulation of energy homeostasis. 23.9 ± 0.6 51.6 ± 2.5 
